



**Data Glacier**

Your Deep Learning Partner

# Exploratory Data Analysis and Proposed Modeling Technique

Healthcare – Persistency of a drug

12/11/2022




**Data Glacier**

Your Deep Learning Partner

# Group FTR


Name	Email	Country	College/Company	Specialization
Fabian Umeh	Fabianumeh335@gmail.com	UK	Teesside University	Data Science
Rukevwe Ovuowo	rukevwe10@gmail.com	Nigeria	GBG Data science Academy	Data Science
Olutayo Oladeinbo	oladeinboolutayo@yahoo.com	UK	Teesside University	Data Science



# Agenda

- Executive Summary
  - Problem Statement
  - Objectives
  - Approach
- EDA
- EDA Summary
- Proposed modeling technique

# Executive Summary



## Problem statement

- One of the challenge for all Pharmaceutical companies is to understand the persistency of drugs as per the physician prescription. To solve this problem ABC pharma company would like the process Automated.

## Objectives

- The overall aim of the analysis part of the project is to provide insights into factors that impact the persistency of drugs, which afterwards will lay the foundation on building a suitable classification model and also propose some modelling technique to be used.

## Approach

- Understanding the dataset
- Identifying the most impactful factors
- Making recommendations.
- Proposed modeling technique




# Data Understanding

data.head()											Bucket Unique Row Id	Variable Patient ID	Variable Description Unique ID of each patient
Ptid	Persistency_Flag	Gender	Race	Ethnicity	Region	Age_Bucket	Ntm_Speciality	Ntm_Specialist_Flag	Ntm_Speciality_Bucket	...	Risk_Family_History_Of	Persistency_Flag	Flag indicating if a patient was persistent or not
Age	Race	Region	Ethnicity	Gender	IDN Indicator	NTM - Physician Specialty	NTM - T-Score	Change in T Score	NTM - Risk Segment	Change in Risk Segment	NTM - Multiple Risk Factors	NTM - Dexa Scan Frequency	Flag indicating if patient falls under multiple risk category (having more than 1 risk) at the time of the NTM Rx (within 365 days prior from rxdate)
Demographics	Demographics	Demographics	Demographics	Demographics	Demographics	Demographics	Demographics	Demographics	Demographics	Demographics	Demographics	Demographics	Demographics
Provider Attributes	Provider Attributes	Provider Attributes	Provider Attributes	Provider Attributes	Provider Attributes	Provider Attributes	Provider Attributes	Provider Attributes	Provider Attributes	Provider Attributes	Provider Attributes	Provider Attributes	Provider Attributes
Clinical Factors	Clinical Factors	Clinical Factors	Clinical Factors	Clinical Factors	Clinical Factors	Clinical Factors	Clinical Factors	Clinical Factors	Clinical Factors	Clinical Factors	Clinical Factors	Clinical Factors	Clinical Factors
Disease/Treatment Factor	Disease/Treatment Factor	Disease/Treatment Factor	Disease/Treatment Factor	Disease/Treatment Factor	Disease/Treatment Factor	Disease/Treatment Factor	Disease/Treatment Factor	Disease/Treatment Factor	Disease/Treatment Factor	Disease/Treatment Factor	Disease/Treatment Factor	Disease/Treatment Factor	Disease/Treatment Factor
Adherence	Adherence	Adherence	Adherence	Adherence	Adherence	Adherence	Adherence	Adherence	Adherence	Adherence	Adherence	Adherence	Adherence
NTM - Comorbidity	NTM - Comorbidity	NTM - Comorbidity	NTM - Comorbidity	NTM - Comorbidity	NTM - Comorbidity	NTM - Comorbidity	NTM - Comorbidity	NTM - Comorbidity	NTM - Comorbidity	NTM - Comorbidity	NTM - Comorbidity	NTM - Comorbidity	Comorbidities are divided into two main categories - Acute and chronic, based on the ICD codes. For chronic disease we are taking complete look back from the first Rx date of NTM therapy and for acute diseases, time period before the NTM OP Rx with one year lookback has been applied
NTM - Concomitancy	NTM - Concomitancy	NTM - Concomitancy	NTM - Concomitancy	NTM - Concomitancy	NTM - Concomitancy	NTM - Concomitancy	NTM - Concomitancy	NTM - Concomitancy	NTM - Concomitancy	NTM - Concomitancy	NTM - Concomitancy	NTM - Concomitancy	Concomitant drugs recorded prior to starting with a therapy(within 365 days prior from first rxdate)
Adherence	Adherence	Adherence	Adherence	Adherence	Adherence	Adherence	Adherence	Adherence	Adherence	Adherence	Adherence	Adherence	Adherence for the therapies


5 rows x 69 columns

- The dataset contains 3424 rows and 69 columns.

# Exploratory data analysis





- The number of cases where the drugs proved to be non-persistent were higher compared to number of persistency cases.
- The dataset reveals that more females partook in this analysis than males.
- People of Caucasian race when compared to other races were the most common in the study.






- The non-Hispanic ethnic group were the most common in the study.
- There were more people from the Midwest and South region compared to other regions.


## Exploratory data analysis



## Exploratory data analysis




- For this study, the majority of people selected are greater than 75 years of age.
- People with a Tscore of >-2.5 have a higher chance of drug being non-persistent.






## Exploratory data analysis




- The chart reveals people with a lower count of risk have a higher chance of drug being non-persistent.



# Summary and recommendation

## EDA SUMMARY


- The dataset contains 3424 rows and 69 columns.
- The number of cases where the drugs proved to be non-persistent were higher compared to number of persistency cases.
- The dataset reveal that more females partook in this analysis than male.
- People of Caucasian race when compared to other races were the most common in the study.
- The non-Hispanic ethnic group were the most common in the study.
- There were more people from the Midwest and South region compared to other regions.
- For this study, most people selected are greater than 75 years of age.
- People with a Tscore of  $>-2.5$  have a higher chance of drug being non-persistent.



# Proposed modeling technique

The project is aimed at using certain factors relative to a patient in classifying successfully whether a drug is persistent or not. From the machine learning aspect of things, the task is a classification task and a binary classification task to be specific. For this project, we will focus on state-of-the-art machine learning classification models to build our drug persistency classifier. They include:

1. Logistic regression model
2. Support vector machines (SVM)
3. K-nearest neighbours (KNN)
4. Gradient Boost model



# Repository details

- Github Repo link: [Ovuowo-Rukevwe/-Healthcare-Persistency-of-a-Drug \(github.com\)](https://github.com/Ovuowo-Rukevwe/-Healthcare-Persistency-of-a-Drug)

# Thank You